KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Accumulated Expenses (2017 - 2026)

Regeneron Pharmaceuticals (REGN) has disclosed Accumulated Expenses for 13 consecutive years, with $2.7 billion as the latest value for Q1 2026.

  • For Q1 2026, Accumulated Expenses rose 21.53% year-over-year to $2.7 billion; the TTM value through Mar 2026 reached $2.7 billion, up 21.53%, while the annual FY2025 figure was $2.9 billion, 13.82% up from the prior year.
  • Accumulated Expenses hit $2.7 billion in Q1 2026 for Regeneron Pharmaceuticals, down from $2.9 billion in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $3.0 billion in Q3 2025 and bottomed at $1.8 billion in Q3 2022.
  • Average Accumulated Expenses over 5 years is $2.4 billion, with a median of $2.4 billion recorded in 2024.
  • Year-over-year, Accumulated Expenses fell 12.84% in 2022 and then surged 47.22% in 2023.
  • Regeneron Pharmaceuticals' Accumulated Expenses stood at $2.1 billion in 2022, then grew by 13.68% to $2.4 billion in 2023, then grew by 7.18% to $2.5 billion in 2024, then rose by 13.82% to $2.9 billion in 2025, then decreased by 5.28% to $2.7 billion in 2026.
  • According to Business Quant data, Accumulated Expenses over the past three periods came in at $2.7 billion, $2.9 billion, and $3.0 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.